IL5 and Alzheimer disease: Despite initial interest in IL-5 blockade for AD treatment, clinical trials with mepolizumab (anti-IL-5 monoclonal antibody) have failed to demonstrate efficacy (66), suggesting a limited role of IL-5 in AD.